kymera gilead - Search News

News

Gilead, Kymera and Sanofi

Gilead and Kymera in pact to develop cancer drugs

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to develop and sell a band of cancer drugs. Under the deal, Kymera could receive up to $750M,

Yahoo Finance · 1h

Kymera’s partnerships with Sanofi and Gilead drive value

Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

pharmaphorum · 2d

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

PharmExec1d

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

PMLive1d

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Morningstar2d

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Morningstar

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results